Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.90
Change (%)0.00 (0.00%)
Volume0
Data as of 12/12/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent NewsMore >>
DateTitle 
11/09/17Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
Top-line, 1-year Superiority Data for NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018   Company to Host Conference Call and Webcast Thursday, November 9, 2017 at 8:30 a.m. ET  WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced financia... 
Printer Friendly Version
10/26/17Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017
WALTHAM, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, announced it will report its third quarter 2017 financial results on Thursday, November 9, 2017 before the U.S. financial markets open.  The Company will host a conference call and webcast at 8:30 a.m. ET to review financial and operational results for the quarter ended September 30, 2017 and pro... 
Printer Friendly Version
10/12/17Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
WALTHAM, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced the promotion of Stephen Kennedy from Chief Technology Officer to Executive Vice President & Chief Operating Officer, effective October 12, 2017.  Mr. Kennedy brings more than 30 years of executive product development, manufacturing, technology assessment and com... 
Printer Friendly Version
10/02/17Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
– Data Demonstrate the Importance of Generating Extracellular Matrix During Ex-Vivo Manufacturing of Cartilage Cell Therapy – – Ex-vivo Production of Extracellular Matrix is Critical to Biomechanical Competence and May Enable Earlier Return to Function After Treatment – – Presence of Extracellular Matrix at Time of Implantation Improves Biomechanical Competence of Cartilage Cell Therapy Compared to Therapies with Only Cells and Scaffold – WALTHAM, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) --... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.